Terns Pharmaceuticals and Rhythm Pharmaceuticals are developing weight loss medicines, with Terns having an upcoming data readout for a promising oral candidate. The anti-obesity space is growing rapidly, attracting both large and small drugmakers seeking significant impact and financial benefits. Terns is developing TERN-601, a mid-stage oral GLP-1 candidate, with a phase 2 trial underway and data expected in the fourth quarter. Additionally, Terns has other pipeline candidates, including TERN-501 and TERN-701.

On the other hand, Rhythm Pharmaceuticals is targeting label expansions for its lone approved therapy, Imcivree, for weight management in patients with specific protein deficiencies. Recent clinical progress includes strong phase 3 results for setmelanotide in patients with obesity from hypothalamic damage, with regulatory applications submitted. Rhythm’s revenue increased by 66.8% in the second quarter, with plans to initiate phase 3 studies for bivamelagon next year.

Both Terns Pharmaceuticals and Rhythm Pharmaceuticals are relatively unknown biotechs developing promising weight loss therapies. Terns’ TERN-601 and Rhythm’s Imcivree and setmelanotide show potential for addressing weight management in different patient populations. The success of these medicines could lead to significant market impact and financial rewards for the companies.

Read more at Yahoo Finance.: 2 Under-the-Radar Stocks That Could Soar